Does tigecycline frequently cause liver enzyme elevation?
Tigecycline, an intravenous glycylcycline antibiotic used for complicated skin/skin structure infections, intra-abdominal infections, and community-acquired pneumonia, commonly elevates liver enzymes. Clinical trial data show transaminase elevations (ALT/AST >3x upper limit of normal) in 15-25% of patients, with rates up to 26% for ALT in some studies.[1][2] The prescribing information lists abnormal liver function tests as "very common" (≥10% incidence).[3]
How often does this happen compared to other antibiotics?
Tigecycline's liver enzyme elevations occur more frequently than with comparators like vancomycin or imipenem. In phase 3 trials, tigecycline groups had ALT elevations in 22-26% vs. 13-17% in control arms.[1][4] Most cases are asymptomatic and reversible upon discontinuation, but severe (grade 3/4) elevations affect 2-5% of patients.[2]
What do real-world studies and post-marketing reports show?
Post-approval data confirm similar rates: a meta-analysis of 5,478 patients reported hepatic adverse events in 9.4%, with enzyme elevations predominant.[5] FDA adverse event reporting flags hepatotoxicity, including rare cases of liver failure, though causality is not always clear.[6] Elevations peak within 7-14 days of starting therapy and resolve in 70-90% without intervention.[4]
Who is most at risk for tigecycline-related liver issues?
Higher risk occurs in patients with baseline liver impairment, prolonged therapy (>14 days), or concurrent hepatotoxins like acetaminophen. Obesity and older age also correlate with increased incidence.[2][7] No strong genetic factors identified, but monitoring is advised for all.
How is liver enzyme elevation managed during treatment?
Guidelines recommend baseline LFTs and weekly monitoring. Hold tigecycline if ALT/AST >5x ULN or bilirubin >2x ULN. Most resolve within 1-4 weeks post-discontinuation; supportive care suffices unless jaundice or coagulopathy develops.[3][8] No specific antidote exists.
Are there alternatives with lower liver risks?
Meropenem or piperacillin-tazobactam show lower transaminitis rates (5-15%) for similar indications. For multidrug-resistant infections, eravacycline has comparable efficacy but slightly lower hepatic events (10-15%).[9][10] Choice depends on resistance patterns and patient factors.
[1]: Tigecycline FDA Label
[2]: ClinicalTrials.gov summaries, e.g., NCT00079547
[3]: Tygacil Summary of Product Characteristics (EU)
[4]: Meagher et al., Clin Infect Dis (2005)
[5]: Cai et al., J Antimicrob Chemother (2011)
[6]: FAERS database via FDA
[7]: Tasina et al., Int J Antimicrob Agents (2011)
[8]: IDSA guidelines on antibiotic stewardship
[9]: Eravacycline prescribing info
[10]: Solomkin et al., Clin Infect Dis (2017)